Cardiac disorders occurred in 26% of patients receiving CAR-T cell therapy, with severe grade 3-5 disorders occurring in 10% of patients and strongly associating with severe cytokine release syndrome.
Cohort (n=126)
No
Cardiac disorders are common but mostly mild following CAR-T cell therapy, and severe cases are strongly associated with higher grade cytokine release syndrome.
Introduction Chimeric antigen receptor T (CAR-T) cells are effective in treating hematological malignancies. However, in patients receiving CAR-T therapy, data characterizing cardiac disorders are limited. Methods 126 patients with hematologic malignancies receiving CAR-T cell therapy were analyzed to determine the impact of CAR-T therapy on occurrence of cardiac disorders, including heart failure, arrhythmias, myocardial infarction, which were defined by the Common Terminology Criteria for Adverse Events (CTCAE). Parameters related to cardiac disorders were detected including myocardial enzyme, NT-proBNP and ejection fraction (EF). Cardiovascular (CV) events included decompensated heart failure (HF), clinically significant arrhythmias and CV death. Results The median age of patients was 56 years (6 to 72 years). 58% patients were male, 62% had multiple myeloma, 20% had lymphoma and 18% had ALL. 33 (26%) patients had cardiac disorders, most of which were grade 1-2. 13 patients (10%) were observed with cardiac disorders grade 3-5, which comprised 5(4%) patients with new-onset HF, 2 (2%) patients with new-onset arrhythmias, 4 (3%) patients with the acute coronary syndrome, 1(1%) patient with myocardial infarction and 1(1%) patient with left ventricular systolic dysfunction. There were 9 CV events (7%) including 6 decompensated heart failure, 1 clinically significant arrhythmias and 2 CV deaths. Among the 33 patients with cardiac disorders, the patients with cardiac disorders CTCAE grade 3-5 had higher grade CRS (grade ≥ 3) than those with cardiac disorders CTCAE grade ≤ 2 ( P 0.001). More patients with cardiac disorders CTCAE grade 3-5 were observed in the cohort who did not receive corticosteroids and/or tocilizumab therapy timely comparing with those who received corticosteroids and/or tocilizumab therapy timely ( P =0.0004). Conclusions Cardiac disorders CAR-T cell therapy were common and associated with occurrence of CRS. However, most cases were mild. For patients with CRS grade 3-5, timely administration of corticosteroids and/or tocilizumab can effectively prevent the occurrence and progression of cardiac disorders.
Qi et al. (Mon,) conducted a cohort in Relapsed/refractory hematologic malignancies (n=126). CAR-T cell therapy was evaluated on Occurrence of cardiac disorders (CTCAE defined). Cardiac disorders occurred in 26% of patients receiving CAR-T cell therapy, with severe grade 3-5 disorders occurring in 10% of patients and strongly associating with severe cytokine release syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: